News & Events
Keyword Search
 
2018 | 2017 | 2016
DateTitle 
05/17/18Obalon Announces Upcoming Conference Presentation
SAN DIEGO, May 17, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced that Andy Rasdal, Chief Executive Officer, and Bill Plovanic, Chief Financial Officer of Obalon, will participate in the following upcoming investor conference:  UBS Global Healthcare Conference Monday, May 21, 2018, Presen... 
05/10/18Obalon Announces First Quarter 2018 Financial Results
SAN DIEGO, May 10, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its unaudited financial results as of and for the first quarter ended March 31, 2018. First Quarter 2018 highlights: Highest number of treating accounts ever, up 40% vs Q4-17 and 300% vs Q1-17 Highest number of patie... 
05/07/18Todd Wood joins Obalon Therapeutics, Inc. as Vice President Global Sales
SAN DIEGO, May 07, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company, announced today that Todd Wood has joined as Vice President Global Sales. Mr. Wood will be responsible for leading field sales, product specialists, sales operations and inside sales support. “Mr. Wood brings deep expertise in high-touch physician relationships and practice engagement to create sustainable revenue in developing markets. He was instrumental... 
05/04/18Obalon Schedules First Quarter 2018 Financial Results Conference Call for May 10, 2018 at 5:00 p.m. Eastern Time
SAN DIEGO, May 04, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced that it plans to release its first quarter 2018 financial results after the market closes on Thursday, May 10, 2018. The company will hold a conference call and simultaneous webcast at 5:00 PM, Eastern Time (2:00 PM Pacific Tim... 
03/05/18Obalon Announces Fourth Quarter and Full Year 2017 Financial Results
SAN DIEGO, March 05, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its audited financial results as of and for the fourth quarter and full year ended December 31, 2017.  Fourth Quarter highlights: Q4-17 total revenue of $3.7 million grew 32% sequentially over Q3-17 Q4-17 U.S. revenu... 
03/05/18Obalon Schedules Fourth Quarter and Year End 2017 Financial Results Conference Call for March 5, 2018 at 5:00 p.m. Eastern Time
SAN DIEGO, March 05, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced that it plans to release its fourth quarter and full year 2017 financial results after the market closes on Monday, March 5, 2018. The company will hold a conference call and simultaneous webcast at 5:00 PM, Eastern Time (2:0... 
02/20/18Obalon’s Audit Committee Investigation of Whistleblower Allegation Finds Complaint Meritless
Company to Host Conference Call Today at 6:00 a.m. PST/ 9:00 a.m. EST SAN DIEGO, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN) today announced the Audit Committee has completed its investigation into a purported whistleblower complaint and concluded that the allegations in the complaint are without merit. On January 23, 2018, Obalon issued a press release announcing the termination of its previously announced offering of common stock and the underwriting agreeme... 
01/23/18Obalon Announces Termination of Public Offering of Common Stock
SAN DIEGO, Jan. 23, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (the “Company” or “Obalon”) (NASDAQ:OBLN) today announced the termination of the underwriting agreement and cancellation of its previously announced public offering (the “Offering”) of 5,454,545 shares of its common stock at a public offering price of $5.50 per share. UBS Investment Bank, Canaccord Genuity and Stifel were acting as joint book-running managers for the offering. BTIG was acting as a co-manager. The offerin... 
01/18/18Obalon Therapeutics Prices Public Offering of Common Stock
SAN DIEGO, Jan. 18, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical device company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announced the pricing of an underwritten public offering of 5,454,545 shares of its common stock at a public offering price of $5.50 per share. The offering is expected to close on or about January 23, 2018, subject to customary closing condition... 
01/16/18Obalon Therapeutics Announces Proposed Public Offering of Common Stock
SAN DIEGO, Jan. 16, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical device company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announced that it is commencing an underwritten public offering of $35 million of shares of its common stock.  Obalon Therapeutics also expects to grant the underwriters a 30-day option to purchase up to an additional $5.25 million of shares of i... 
01/05/18Obalon Reports Record Preliminary, Unaudited Revenue for the Fourth Quarter and Full Year 2017
SAN DIEGO, Jan. 05, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN) today reported that it achieved preliminary, unaudited revenue of approximately $3.9 million for the fourth quarter ended December 31, 2017, an estimated increase of approximately 400% over the fourth quarter of 2016. For the full year 2017, total preliminary, unaudited revenue is expected to be $10.1 million, an estimated increase of approximately 200% over 2016. These preliminary results are subject to compl... 
01/04/18Obalon Schedules Fourth Quarter and Full Year 2017 Preliminary, Unaudited Revenue and Business Update Conference Call for January 5, 2018 at 8:30 a.m. Eastern Time
SAN DIEGO, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced that it plans to release its preliminary, unaudited revenue for the fourth quarter and full year 2017 before the market opens on Friday, January 5, 2018. The company will hold a conference call and simultaneous webcast at 8... 
Webcast ImageWebcast
Obalon Therapeutics, Inc. at UBS Global Healthcare Conference (Replay)
05/21/18 at 9:30 a.m. ET
Obalon Therapeutics, Inc. at UBS Global Healthcare Conference
Monday, May 21, 2018 9:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Upcoming Events
There are currently no events scheduled.
Past Events
DateTitle
05/10/18 5:00 p.m. ET
Obalon First Quarter 2018 Financial Results Conference Call
03/05/18 5:00 p.m. ET
Q4 2017 Obalon Therapeutics, Inc. Earnings Conference Call
11/03/17 8:30 a.m. ET
Obalon Third Quarter 2017 Conference Call
08/02/17 8:30 a.m. ET
Obalon Second Quarter 2017 Conference Call
05/10/17 8:30 a.m. ET
Obalon First Quarter 2017 Conference Call
02/23/17 8:30 a.m. ET
Obalon Fourth Quarter 2016 Conference Call
11/11/16 5:00 a.m. PT
Obalon Third Quarter 2016 Conference Call
IMPORTANT SAFETY INFORMATION
The Obalon Balloon System is intended for adults with a body mass index (BMI) of 30 to 40 kg/m2 willing to follow a diet and exercise program. All Obalon balloons must be removed in 6 months. Patients with prior weight loss surgeries are not eligible. The most common side effects reported were mild abdominal pain and nausea which typically resolved within two weeks. You must take daily acid-blocking medicine prescribed by your doctor. For full Important Safety Information click on Safety Information and Patient Labeling